Physician profile
David Perrick
NPI 1336255280
$1,194.15
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $618 · 2020: $279 · 2021: $298.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $230.61 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $176.81 | 2019-2021 | |
| Genzyme Corporation | $165.35 | 2019-2021 | |
| Genentech USA, INC. | $123.65 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.91 | 2019-2021 | |
| Optinose US, INC. | $108.86 | 2019-2021 | |
| Alk-Abello, INC | $78.56 | 2019-2021 | |
| Glaxosmithkline, LLC. | $56.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $36.00 | 2019-2020 | |
| Kaleo, INC. | $30.26 | 2019-2020 | |
| Biocryst US Sales Co., LLC | $21.21 | 2021 | |
| Octapharma USA, INC. | $17.20 | 2021 | |
| Seqirus USA INC | $13.53 | 2019 | |
| Pfizer INC. | $12.54 | 2020 | |
| Hospira, INC. | $11.99 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Perrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.